During the last three months, 7 analysts shared their evaluations of Allogene Therapeutics (NASDAQ:ALLO), revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Analysts’ evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.66, with a high estimate of $17.00 and a low estimate of $4.60. Witnessing a positive shift, the current average has risen by 12.57% from the previous average price …